Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 2
1979 6
1980 7
1981 5
1982 7
1983 13
1984 5
1985 14
1986 13
1987 11
1988 23
1989 35
1990 45
1991 38
1992 36
1993 53
1994 47
1995 48
1996 64
1997 52
1998 38
1999 69
2000 98
2001 89
2002 99
2003 118
2004 136
2005 152
2006 184
2007 205
2008 194
2009 267
2010 257
2011 286
2012 327
2013 358
2014 446
2015 557
2016 657
2017 633
2018 746
2019 914
2020 1014
2021 692
Text availability
Article attribute
Article type
Publication date

Search Results

7,965 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis.
Bonnot PE, Piessen G, Kepenekian V, Decullier E, Pocard M, Meunier B, Bereder JM, Abboud K, Marchal F, Quenet F, Goere D, Msika S, Arvieux C, Pirro N, Wernert R, Rat P, Gagnière J, Lefevre JH, Courvoisier T, Kianmanesh R, Vaudoyer D, Rivoire M, Meeus P, Passot G, Glehen O; FREGAT and BIG-RENAPE Networks. Bonnot PE, et al. J Clin Oncol. 2019 Aug 10;37(23):2028-2040. doi: 10.1200/JCO.18.01688. Epub 2019 May 14. J Clin Oncol. 2019. PMID: 31084544
PURPOSE: Gastric cancer (GC) with peritoneal metastases (PMs) is a poor prognostic evolution. Cytoreductive surgery (CRS) yields promising results, but the impact of hyperthermic intraperitoneal chemotherapy (HIPEC) r …
PURPOSE: Gastric cancer (GC) with peritoneal metastases (PMs) is a poor prognostic evolution. Cytoreductive
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer.
Seshadri RA, Glehen O. Seshadri RA, et al. World J Gastroenterol. 2016 Jan 21;22(3):1114-30. doi: 10.3748/wjg.v22.i3.1114. World J Gastroenterol. 2016. PMID: 26811651 Free PMC article. Review.
Gastric cancer associated peritoneal carcinomatosis (GCPC) has a poor prognosis with a median survival of less than one year. ...Since recurrent gastric cancer remains confined to the abdominal cavity in many patients, regional therapies like ag
Gastric cancer associated peritoneal carcinomatosis (GCPC) has a poor prognosis with a median survival of less than one
[Hyperthermic intraperitoneal chemotherapy].
Leebmann H, Piso P. Leebmann H, et al. Chirurg. 2019 Jul;90(7):593-604. doi: 10.1007/s00104-019-0982-5. Chirurg. 2019. PMID: 31190081 Review. German.
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are recognized as the standard of care for selected patients with peritoneal malignancies. A complete macroscopic cytoreduction is the basis for a su
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are recognized as the s
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II).
Koemans WJ, van der Kaaij RT, Boot H, Buffart T, Veenhof AAFA, Hartemink KJ, Grootscholten C, Snaebjornsson P, Retel VP, van Tinteren H, Vanhoutvin S, van der Noort V, Houwink A, Hahn C, Huitema ADR, Lahaye M, Los M, van den Barselaar P, Imhof O, Aalbers A, van Dam GM, van Etten B, Wijnhoven BPL, Luyer MDP, Boerma D, van Sandick JW. Koemans WJ, et al. BMC Cancer. 2019 May 6;19(1):420. doi: 10.1186/s12885-019-5640-2. BMC Cancer. 2019. PMID: 31060544 Free PMC article.
BACKGROUND: At present, palliative systemic chemotherapy is the standard treatment in the Netherlands for gastric cancer patients with peritoneal dissemination. ...The combination of a radical gastrectomy with cytoreductive surgery (CRS) …
BACKGROUND: At present, palliative systemic chemotherapy is the standard treatment in the Netherlands for gastric cancer
Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review.
Auer RC, Sivajohanathan D, Biagi J, Conner J, Kennedy E, May T. Auer RC, et al. Eur J Cancer. 2020 Mar;127:76-95. doi: 10.1016/j.ejca.2019.10.034. Epub 2020 Jan 24. Eur J Cancer. 2020. PMID: 31986452
The purpose of the present review was to describe evidence-based indications for hyperthermic intraperitoneal chemotherapy (HIPEC), with cytoreductive surgery (CRS), in patients with a diagnosis of mesothelioma, appendiceal (including appendicea …
The purpose of the present review was to describe evidence-based indications for hyperthermic intraperitoneal chemotherapy
Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysis.
Huo YR, Richards A, Liauw W, Morris DL. Huo YR, et al. Eur J Surg Oncol. 2015 Dec;41(12):1578-89. doi: 10.1016/j.ejso.2015.08.172. Epub 2015 Sep 25. Eur J Surg Oncol. 2015. PMID: 26453145 Review.
PURPOSE: Emerging evidence suggests that hyperthermic intraperitoneal chemotherapy (HIPEC) with cytoreductive surgery (CRS) shows a survival benefit over CRS alone for patients with epithelial ovarian carcinoma (EOC). ...Meta-analysis of …
PURPOSE: Emerging evidence suggests that hyperthermic intraperitoneal chemotherapy (HIPEC) with cytoreductive
Best practice for perioperative management of patients with cytoreductive surgery and HIPEC.
Raspé C, Flöther L, Schneider R, Bucher M, Piso P. Raspé C, et al. Eur J Surg Oncol. 2017 Jun;43(6):1013-1027. doi: 10.1016/j.ejso.2016.09.008. Epub 2016 Sep 28. Eur J Surg Oncol. 2017. PMID: 27727026 Review.
Due to the significantly improved outcome and quality of life of patients with different tumor entities after cytoreductive surgery (CRS) and HIPEC, there is an increasing number of centers performing CRS and HIPEC procedures. ...Clinical pathways have to be …
Due to the significantly improved outcome and quality of life of patients with different tumor entities after cytoreductive surger
Update on Cancer Treatment in Exotics.
Zehnder A, Graham J, Antonissen G. Zehnder A, et al. Vet Clin North Am Exot Anim Pract. 2018 May;21(2):465-509. doi: 10.1016/j.cvex.2018.01.012. Vet Clin North Am Exot Anim Pract. 2018. PMID: 29655479 Free article. Review.
Treatment options for animals with cancer are rapidly expanding, including in exotic animal medicine. ...This review provides an update on cancer treatment in exotic animal species. The Exotic Species Cancer Research Alliance accumulates clinical cases in a c …
Treatment options for animals with cancer are rapidly expanding, including in exotic animal medicine. ...This review provides an upda …
Imaging before cytoreductive surgery in advanced ovarian cancer patients.
Rizzo S, Del Grande M, Manganaro L, Papadia A, Del Grande F. Rizzo S, et al. Int J Gynecol Cancer. 2020 Jan;30(1):133-138. doi: 10.1136/ijgc-2019-000819. Epub 2019 Nov 21. Int J Gynecol Cancer. 2020. PMID: 31754068 Review.
Appropriate and accurate pre-operative imaging in epithelial ovarian cancer patients may allow selection of patients that may mostly benefit either from primary cytoreductive surgery or from neoadjuvant chemotherapy. ...Positron emission tomography (PE …
Appropriate and accurate pre-operative imaging in epithelial ovarian cancer patients may allow selection of patients that may mostly …
Cytoreduction and hyperthermic intraperitoneal chemotherapy in metastatic colorectal cancer.
Eng OS, Turaga KK. Eng OS, et al. J Surg Oncol. 2019 Apr;119(5):613-615. doi: 10.1002/jso.25438. Epub 2019 Mar 10. J Surg Oncol. 2019. PMID: 30852849 Review.
As the management of metastatic colorectal cancer (CRC) has evolved over the past decades, optimal management of CRC with peritoneal metastases remains controversial, especially about cytoreductive surgery and hyperthermic intraperiton
As the management of metastatic colorectal cancer (CRC) has evolved over the past decades, optimal management of CRC with peritone
7,965 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page